MXPA05009242A - Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. - Google Patents
Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.Info
- Publication number
- MXPA05009242A MXPA05009242A MXPA05009242A MXPA05009242A MXPA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- type
- treatment
- pde5 inhibitors
- substantial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de un inhibidor de la PDE5 sin actividad inhibidora sustancial de la PDE2, o una sal farmaceuticamente aceptable del mismo en la preparacion de un medicamento para el tratamiento de la diabetes tipo 1. Un procedimiento de tratamiento de la diabetes de tipo 1 en un individuo que padece la diabetes de tipo 1, cuyo procedimiento comprende la administracion a dicho individuo de una cantidad eficaz de un inhibidor de la PDE5 sin actividad inhibidora sustancial de la PDE2, o un a sal farmaceuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45527703P | 2003-03-17 | 2003-03-17 | |
PCT/IB2004/000696 WO2004082667A1 (en) | 2003-03-17 | 2004-03-04 | Treatment of type 1 diabetes with pde5 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05009242A true MXPA05009242A (es) | 2006-04-18 |
Family
ID=33029981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05009242A MXPA05009242A (es) | 2003-03-17 | 2004-03-04 | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1605925A1 (es) |
JP (1) | JP2006520777A (es) |
BR (1) | BRPI0408500A (es) |
CA (1) | CA2519357A1 (es) |
MX (1) | MXPA05009242A (es) |
TW (1) | TW200503666A (es) |
WO (1) | WO2004082667A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050234068A1 (en) * | 2004-04-19 | 2005-10-20 | Baldwin Dalton D | Composition and method of decreasing renal ischemic damage |
EP1909793A2 (de) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben |
US7772277B2 (en) * | 2005-08-04 | 2010-08-10 | Transform Pharmaceuticals, Inc. | Formulations comprising fenofibrate and a statin, and related methods of treatment |
BRPI0716134A2 (pt) | 2006-09-07 | 2013-09-17 | Nycomed Gmbh | tratamento de combinaÇço para diabetes mellitus |
MX2009013354A (es) | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
JP6469015B2 (ja) * | 2012-11-13 | 2019-02-13 | ニューサート サイエンシーズ, インコーポレイテッド | エネルギー代謝を増大させるための組成物および方法 |
AU2013370966A1 (en) | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
AU2014347668A1 (en) | 2013-11-05 | 2016-05-19 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023091A2 (en) * | 1998-10-15 | 2000-04-27 | Bioimage A/S | Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
DE19944161A1 (de) * | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
CA2414352A1 (en) * | 2000-06-30 | 2002-01-10 | Pfizer Inc. | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
CN1446084A (zh) * | 2000-08-11 | 2003-10-01 | 辉瑞大药厂 | 胰岛素抗性综合症的治疗 |
WO2002060422A2 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
GB0106631D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
ES2241994T3 (es) * | 2001-03-16 | 2005-11-01 | Pfizer Inc. | Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc. |
US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
-
2004
- 2004-03-04 JP JP2006506327A patent/JP2006520777A/ja active Pending
- 2004-03-04 BR BRPI0408500-0A patent/BRPI0408500A/pt not_active Application Discontinuation
- 2004-03-04 EP EP04717183A patent/EP1605925A1/en not_active Withdrawn
- 2004-03-04 CA CA002519357A patent/CA2519357A1/en not_active Abandoned
- 2004-03-04 WO PCT/IB2004/000696 patent/WO2004082667A1/en not_active Application Discontinuation
- 2004-03-04 MX MXPA05009242A patent/MXPA05009242A/es not_active Application Discontinuation
- 2004-03-17 TW TW093107099A patent/TW200503666A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2519357A1 (en) | 2004-09-30 |
JP2006520777A (ja) | 2006-09-14 |
WO2004082667A1 (en) | 2004-09-30 |
BRPI0408500A (pt) | 2006-03-07 |
EP1605925A1 (en) | 2005-12-21 |
TW200503666A (en) | 2005-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
AU2003268144A1 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
IN2005KO00312A (es) | ||
HK1086186A1 (en) | Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain | |
TW200639159A (en) | Treatment of pain | |
TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
WO2004103297A3 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
AU4258101A (en) | Combination therapies with vascular damaging activity | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
WO2004006849A3 (en) | Combinations of drugs for the treatment of neoplasms | |
TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
EP1695969A4 (en) | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE | |
TW200603792A (en) | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors | |
WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
TW200642688A (en) | New use of PDE7 inhibitors | |
MXPA05004920A (es) | Combinacion que comprende un inhibidor cdk y cisplatin. | |
GB0313386D0 (en) | Treatment of disease | |
TW200610524A (en) | Medicine for prevention or treatment of diabetes | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
TW200608965A (en) | Medicine for prevention or treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |